Britta Siegmund - Free Univ Berlin | 人才画像

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 11 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

S52 Corticosteroid-Free Efficacy and Safety of Ulcerative Colitis Patients Receiving Once-Daily Obefazimod in an Open-Label, 96-Week Maintenance Study among Patients Who Were Receiving Concomitant Corticosteroids at Induction Baseline

Severine Vermeire, Laurent Peyrin-Biroulet,Silvio Danese,Parambir S. Dulai,Marla C. Dubinsky,Herbert Tilg,Britta Siegmund, Tadakazu Hisamatsu,Josianne Nitcheu, Chris J. Rabbat, Bruce E. Sands

American Journal of Gastroenterology（2024）

引用0浏览0引用

S9 Efficacy and Safety of Obefazimod in Patients with Ulcerative Colitis at Week 48 of an Open-Label Maintenance Study among Clinical Nonresponses at Week 8 of the Phase 2b Induction Trial

Bruce E. Sands, Laurent Peyrin-Biroulet,Silvio Danese,Parambir S. Dulai,Marla C. Dubinsky,Herbert Tilg,Britta Siegmund, Tadakazu Hisamatsu,Josianne Nitcheu, Chris J. Rabbat,Severine Vermeire

American Journal of Gastroenterology（2024）

引用0浏览0引用

S2 Impact of Obefazimod Induction Therapy on Histologic and Combined Histologic and Endoscopic Outcomes in Patients with Moderately to Severely Active Ulcerative Colitis: Week 8 Results from the Phase 2b Induction Trial

Laurent Peyrin-Biroulet, Bruce E. Sands,Silvio Danese,Parambir S. Dulai,Marla C. Dubinsky,Herbert Tilg,Britta Siegmund, Tadakazu Hisamatsu,Josianne Nitcheu, Chris J. Rabbat,Severine Vermeire

American Journal of Gastroenterology（2024）

引用0浏览0引用

S1137 the Impact of Etrasimod on the Transcriptome in Colon Biopsies Using RNA-Seq: Data from ELEVATE UC 52 and ELEVATE UC 12 Phase 3 Clinical Trials

Britta Siegmund,Catherine M. Crosby,Rathi D. Ryan,Maria T. Abreu,Séverine Vermeire,Iris Dotan,Keren M. Rabinowitz,Xiang Guo,H. Kiyomi Komori,Martina Goetsch,John C. Woolcott,Silvio Danese

American Journal of Gastroenterology（2024）

引用0浏览0引用

Risankizumab is Associated with Normalization of Biomarkers in Patients with Crohn’s Disease: Results from the Phase 3 ADVANCE, MOTIVATE, and FORTIFY Studies

Raja Atreya,Marc Ferrante,Remo Panaccione,Brian Feagan,Oksana Shchukina,Vipul Jairath,Florian Rieder,Tadakazu Hisamatsu,Britta Siegmund,Kristina Kligys,Alexandra Song,Javier Zambrano,Madhuja Mallick,Yafei Zhang,Alessandro Armuzzi,Geert D'Haens

Journal of Crohn's & colitis (2024)

引用0浏览0WOS引用

S1138 Characterization of the Effect of Etrasimod on Peripheral Blood Mononuclear Cells: Data from ELEVATE UC 52 and ELEVATE UC 12 Phase 3 Clinical Trials

Britta Siegmund,Rathi D. Ryan,Catherine M. Crosby,Maria T. Abreu,Séverine Vermeire,Iris Dotan,Keren M. Rabinowitz,Xiang Guo,H. Kiyomi Komori,Martina Goetsch,John C. Woolcott,Silvio Danese

American Journal of Gastroenterology（2024）

引用0浏览0引用

S1493 the Impact of Mirikizumab Induction, Maintenance, and Long-Term Treatment on Disease Clearance in Patients with Moderately to Severely Active Ulcerative Colitis: Post-Hoc Analysis of LUCENT Trials

Jean-Frédéric Colombel,Taku Kobayashi,Jianmin Wu,Baojin Zhu,Vipul Jairath,Isabel Redondo,Richard Moses,Corey A. Siegel,Britta Siegmund,Fernando Magro

American Journal of Gastroenterology（2024）

引用0浏览0引用

Response to Etrasimod Treatment in Ulcerative Colitis is Associated with a Reduction of Circulating B and Pro-Inflammatory T Cells: a Single-Cell-based Post-Hoc Sub-Analysis of the ELEVATE UC 52 Trial

Carl Weidinger,Miha Milek, Julia Hecker,Lea-Maxie Haag,Inka Freise,Benedikt Obermayer,Dieter Beule,Rathi D. Ryan,Catherine Crosby,Britta Siegmund

GASTROENTEROLOGYno. 5 (2024): S1405-S1405

引用0浏览0引用

Tu1743 ETRASIMOD FOR THE TREATMENT OF ULCERATIVE COLITIS: ANALYSIS OF INFECTION RATES FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 CLINICAL TRIALS

Miguel Regueiro,Britta Siegmund, Andrés Yarur,Flávio Steinwurz,Krisztina Gecse,Martina Goetsch, Abhishek Bhattacharjee, Joseph M. Wu,Jesse Green,Aoibhinn McDonnell,Catherine Crosby,Krisztina Lazin,Diogo Branquinho,Irene Modesto,María T. Abreu

Gastroenterologyno. 6 (2023): S-1105

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn